Travere Therapeutics price target raised to $47 from $45 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...
Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently
We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against other ...
Travere therapeutics officer sells shares worth over $1.35 million
Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...
Pharmaceutical Technology2d
Travere takes rare disease kidney drug to FDA despite failed trial
Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life ...
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its target price hoisted by equities researchers at Canaccord Genuity Group from $22.00 to $45.00 in a research report issued on ...
Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday?
We recently published a list of These 10 Companies Led Tuesday’s Charge. In this article, we are going to take a look at ...
Yahoo Finance2d
Travere Therapeutics, Inc. (TVTX)
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20 ...